Narrative updates are currently in beta.

Back to narrative

Update shared on15 Aug 2025

AnalystConsensusTarget's Fair Value
US$23.00
32.2% undervalued intrinsic discount
15 Aug
US$15.60
Loading
1Y
-5.1%
7D
15.0%

Cellebrite DI’s consensus price target held steady at $23.00 as analysts factor in near-term headwinds from delayed federal spending and efficiency impacts, yet remain positive about long-term growth driven by healthy demand and anticipated federal certifications.


Analyst Commentary


  • Lowered Q2 results and second half guidance due to ongoing efficiency impacts and customer budget pauses.
  • Federal agency clients delayed spending, but demand for identity and data security remains healthy in priority sectors.
  • Anticipated achievement of FedRAMP High ATO status by early 2026 expected to unlock further cloud-related Federal growth.
  • Industry-wide shift in target price methodologies, with new 2026-based valuations influencing current price expectations.
  • Bullish analysts maintain positive ratings based on long-term prospects, despite near-term headwinds.

What's in the News


  • Cellebrite provided Q3 2025 revenue guidance of $121–$126 million and ARR of $435–$445 million; full-year 2025 revenue guidance is $465–$475 million with ARR of $460–$475 million.
  • Thomas E. Hogan has been appointed CEO after serving as interim CEO; he brings over 40 years of technology and software leadership experience.
  • David Barter has been named CFO, succeeding Dana Gerner; Barter brings extensive public company finance experience, notably as CFO at New Relic, C3.ai, and Model N.
  • Cellebrite expanded its partnership with the National Center for Missing and Exploited Children, integrating the NCMEC CyberTipline hash value list into its forensic software to aid in faster identification of CSAM and bolster child protection efforts globally.

Valuation Changes


Summary of Valuation Changes for Cellebrite DI

  • The Consensus Analyst Price Target remained effectively unchanged, at $23.00.
  • The Future P/E for Cellebrite DI remained effectively unchanged, moving only marginally from 71.68x to 71.93x.
  • The Discount Rate for Cellebrite DI remained effectively unchanged, at 10.73%.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.